Tezepelumab is a monoclonal IgG2 antibody that exerts its effect by blocking the interaction between human TSLP and TSLPR and thus reduces the production of different cytokines, which is responsible for various debilitating pathophysiology of asthma. The gene discussed is TSLP; the disease is asthma.